Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Greece

- PMLiVE

Novartis gets FDA panel backing for biosimilar Enbrel

However Amgen claims patent protection for the psoriatic arthritis therapy is valid until 2029

Novartis plots digital transformation in medical education

Outlines benefits of greater use of technology, including transparency and reach

Roche Basel Switzerland

Roche’s MS drug Ocrevus awarded priority review by FDA

Comes as Swiss company files the therapy with the FDA and EMA

Novartis Gehry Building

Heart failure drug Entresto ‘could save 28,000 lives a year’

New independent report looks set to boost sales of Novartis’ drug into blockbuster territory

National Institute for Health and Care Excellence NICE logo

NICE backs five new drugs after discounts agreed

Includes Novartis’ previously rejected lung cancer and melanoma therapies Zykadia and Mekinist

- PMLiVE

GSK’s triple COPD therapy tops Symbicort in phase III trial

Once-daily, single inhaler combination treatment showed “significant” improvement in lung function

- PMLiVE

Ariad files early marketing application for brigatinib

Second-line lung cancer therapy could be on the market by early 2017

Deal Watch May 2016

Novartis, Quintiles and Sanofi are among those featured in this month’s round-up of pharma deal activity

- PMLiVE

GSK brings forward triple COPD therapy filing in US

Intends to file the three-drug respiratory therapy by the end of 2016

Biogen Idec building

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Once-monthly, self-administered Zinbryta ‘significantly’ reduces relapse rate

Novartis building

Novartis says Cosentyx is ‘outpacing competitors’

Claims new psoriasis drug has almost a third of the market share in Germany alone

Novartis Gehry Building

Novartis pushes the accelerator with new Entresto trials

Looks to kick-start sales of its heart failure drug with new study programme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links